The landscape of nanomedicines: An expert perspective
The field of nanotechnology is at the forefront of a scientific revolution, where the term "nano" transcends mere size and opens the door to enormous possibilities. In the context of drug development, the selection of a suitable drug delivery system (corresponding to a certain active pharm...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Nikolić Ines [verfasserIn] Filipić Brankica [verfasserIn] Petrović Marija [verfasserIn] Jordan Olivier [verfasserIn] Savić Snežana [verfasserIn] Borchard Gerrit [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
srp |
| Erschienen: |
2023 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Arhiv za farmaciju - Pharmaceutical Association of Serbia, Belgrade, Serbia, 2018, 73(2023), 5, Seite 390-403 |
|---|---|
| Übergeordnetes Werk: |
volume:73 ; year:2023 ; number:5 ; pages:390-403 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.5937/arhfarm73-46686 |
|---|
| Katalog-ID: |
DOAJ099418371 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ099418371 | ||
| 003 | DE-627 | ||
| 005 | 20240414031918.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240414s2023 xx |||||o 00| ||srp c | ||
| 024 | 7 | |a 10.5937/arhfarm73-46686 |2 doi | |
| 035 | |a (DE-627)DOAJ099418371 | ||
| 035 | |a (DE-599)DOAJ9f518f6a5835435db58f8c14d2af54f0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a srp | ||
| 050 | 0 | |a RS1-441 | |
| 100 | 0 | |a Nikolić Ines |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The landscape of nanomedicines: An expert perspective |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The field of nanotechnology is at the forefront of a scientific revolution, where the term "nano" transcends mere size and opens the door to enormous possibilities. In the context of drug development, the selection of a suitable drug delivery system (corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly, nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining recognition for addressing healthcare issues. While these products hold immense promise, they have faced certain complexities in their translation from the preclinical to the clinical setting, reflected in the lack of proper assessment protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their significance. However, the relatively modest number of approved nanomedicines compared to the extensive research efforts raises important questions and underscores areas of uncertainty. This article provides an overview of the challenges in defining nanomedicines, their properties, the complexities of regulatory frameworks, and the imperative for standardized characterization protocols. | ||
| 650 | 4 | |a nanomedicines | |
| 650 | 4 | |a nanoparticles | |
| 650 | 4 | |a characterization protocols | |
| 650 | 4 | |a regulation of nanomedicines | |
| 653 | 0 | |a Pharmacy and materia medica | |
| 700 | 0 | |a Filipić Brankica |e verfasserin |4 aut | |
| 700 | 0 | |a Petrović Marija |e verfasserin |4 aut | |
| 700 | 0 | |a Jordan Olivier |e verfasserin |4 aut | |
| 700 | 0 | |a Savić Snežana |e verfasserin |4 aut | |
| 700 | 0 | |a Borchard Gerrit |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Arhiv za farmaciju |d Pharmaceutical Association of Serbia, Belgrade, Serbia, 2018 |g 73(2023), 5, Seite 390-403 |w (DE-627)1692190660 |x 22178767 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2023 |g number:5 |g pages:390-403 |
| 856 | 4 | 0 | |u https://doi.org/10.5937/arhfarm73-46686 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/9f518f6a5835435db58f8c14d2af54f0 |z kostenfrei |
| 856 | 4 | 0 | |u https://scindeks-clanci.ceon.rs/data/pdf/0004-1963/2023/0004-19632305390N.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/0004-1963 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2217-8767 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2023 |e 5 |h 390-403 | ||
| author_variant |
n i ni f b fb p m pm j o jo s s ss b g bg |
|---|---|
| matchkey_str |
article:22178767:2023----::hlnsaefaoeiieaep |
| hierarchy_sort_str |
2023 |
| callnumber-subject-code |
RS |
| publishDate |
2023 |
| allfields |
10.5937/arhfarm73-46686 doi (DE-627)DOAJ099418371 (DE-599)DOAJ9f518f6a5835435db58f8c14d2af54f0 DE-627 ger DE-627 rakwb srp RS1-441 Nikolić Ines verfasserin aut The landscape of nanomedicines: An expert perspective 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The field of nanotechnology is at the forefront of a scientific revolution, where the term "nano" transcends mere size and opens the door to enormous possibilities. In the context of drug development, the selection of a suitable drug delivery system (corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly, nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining recognition for addressing healthcare issues. While these products hold immense promise, they have faced certain complexities in their translation from the preclinical to the clinical setting, reflected in the lack of proper assessment protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their significance. However, the relatively modest number of approved nanomedicines compared to the extensive research efforts raises important questions and underscores areas of uncertainty. This article provides an overview of the challenges in defining nanomedicines, their properties, the complexities of regulatory frameworks, and the imperative for standardized characterization protocols. nanomedicines nanoparticles characterization protocols regulation of nanomedicines Pharmacy and materia medica Filipić Brankica verfasserin aut Petrović Marija verfasserin aut Jordan Olivier verfasserin aut Savić Snežana verfasserin aut Borchard Gerrit verfasserin aut In Arhiv za farmaciju Pharmaceutical Association of Serbia, Belgrade, Serbia, 2018 73(2023), 5, Seite 390-403 (DE-627)1692190660 22178767 nnns volume:73 year:2023 number:5 pages:390-403 https://doi.org/10.5937/arhfarm73-46686 kostenfrei https://doaj.org/article/9f518f6a5835435db58f8c14d2af54f0 kostenfrei https://scindeks-clanci.ceon.rs/data/pdf/0004-1963/2023/0004-19632305390N.pdf kostenfrei https://doaj.org/toc/0004-1963 Journal toc kostenfrei https://doaj.org/toc/2217-8767 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 73 2023 5 390-403 |
| spelling |
10.5937/arhfarm73-46686 doi (DE-627)DOAJ099418371 (DE-599)DOAJ9f518f6a5835435db58f8c14d2af54f0 DE-627 ger DE-627 rakwb srp RS1-441 Nikolić Ines verfasserin aut The landscape of nanomedicines: An expert perspective 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The field of nanotechnology is at the forefront of a scientific revolution, where the term "nano" transcends mere size and opens the door to enormous possibilities. In the context of drug development, the selection of a suitable drug delivery system (corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly, nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining recognition for addressing healthcare issues. While these products hold immense promise, they have faced certain complexities in their translation from the preclinical to the clinical setting, reflected in the lack of proper assessment protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their significance. However, the relatively modest number of approved nanomedicines compared to the extensive research efforts raises important questions and underscores areas of uncertainty. This article provides an overview of the challenges in defining nanomedicines, their properties, the complexities of regulatory frameworks, and the imperative for standardized characterization protocols. nanomedicines nanoparticles characterization protocols regulation of nanomedicines Pharmacy and materia medica Filipić Brankica verfasserin aut Petrović Marija verfasserin aut Jordan Olivier verfasserin aut Savić Snežana verfasserin aut Borchard Gerrit verfasserin aut In Arhiv za farmaciju Pharmaceutical Association of Serbia, Belgrade, Serbia, 2018 73(2023), 5, Seite 390-403 (DE-627)1692190660 22178767 nnns volume:73 year:2023 number:5 pages:390-403 https://doi.org/10.5937/arhfarm73-46686 kostenfrei https://doaj.org/article/9f518f6a5835435db58f8c14d2af54f0 kostenfrei https://scindeks-clanci.ceon.rs/data/pdf/0004-1963/2023/0004-19632305390N.pdf kostenfrei https://doaj.org/toc/0004-1963 Journal toc kostenfrei https://doaj.org/toc/2217-8767 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 73 2023 5 390-403 |
| allfields_unstemmed |
10.5937/arhfarm73-46686 doi (DE-627)DOAJ099418371 (DE-599)DOAJ9f518f6a5835435db58f8c14d2af54f0 DE-627 ger DE-627 rakwb srp RS1-441 Nikolić Ines verfasserin aut The landscape of nanomedicines: An expert perspective 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The field of nanotechnology is at the forefront of a scientific revolution, where the term "nano" transcends mere size and opens the door to enormous possibilities. In the context of drug development, the selection of a suitable drug delivery system (corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly, nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining recognition for addressing healthcare issues. While these products hold immense promise, they have faced certain complexities in their translation from the preclinical to the clinical setting, reflected in the lack of proper assessment protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their significance. However, the relatively modest number of approved nanomedicines compared to the extensive research efforts raises important questions and underscores areas of uncertainty. This article provides an overview of the challenges in defining nanomedicines, their properties, the complexities of regulatory frameworks, and the imperative for standardized characterization protocols. nanomedicines nanoparticles characterization protocols regulation of nanomedicines Pharmacy and materia medica Filipić Brankica verfasserin aut Petrović Marija verfasserin aut Jordan Olivier verfasserin aut Savić Snežana verfasserin aut Borchard Gerrit verfasserin aut In Arhiv za farmaciju Pharmaceutical Association of Serbia, Belgrade, Serbia, 2018 73(2023), 5, Seite 390-403 (DE-627)1692190660 22178767 nnns volume:73 year:2023 number:5 pages:390-403 https://doi.org/10.5937/arhfarm73-46686 kostenfrei https://doaj.org/article/9f518f6a5835435db58f8c14d2af54f0 kostenfrei https://scindeks-clanci.ceon.rs/data/pdf/0004-1963/2023/0004-19632305390N.pdf kostenfrei https://doaj.org/toc/0004-1963 Journal toc kostenfrei https://doaj.org/toc/2217-8767 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 73 2023 5 390-403 |
| allfieldsGer |
10.5937/arhfarm73-46686 doi (DE-627)DOAJ099418371 (DE-599)DOAJ9f518f6a5835435db58f8c14d2af54f0 DE-627 ger DE-627 rakwb srp RS1-441 Nikolić Ines verfasserin aut The landscape of nanomedicines: An expert perspective 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The field of nanotechnology is at the forefront of a scientific revolution, where the term "nano" transcends mere size and opens the door to enormous possibilities. In the context of drug development, the selection of a suitable drug delivery system (corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly, nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining recognition for addressing healthcare issues. While these products hold immense promise, they have faced certain complexities in their translation from the preclinical to the clinical setting, reflected in the lack of proper assessment protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their significance. However, the relatively modest number of approved nanomedicines compared to the extensive research efforts raises important questions and underscores areas of uncertainty. This article provides an overview of the challenges in defining nanomedicines, their properties, the complexities of regulatory frameworks, and the imperative for standardized characterization protocols. nanomedicines nanoparticles characterization protocols regulation of nanomedicines Pharmacy and materia medica Filipić Brankica verfasserin aut Petrović Marija verfasserin aut Jordan Olivier verfasserin aut Savić Snežana verfasserin aut Borchard Gerrit verfasserin aut In Arhiv za farmaciju Pharmaceutical Association of Serbia, Belgrade, Serbia, 2018 73(2023), 5, Seite 390-403 (DE-627)1692190660 22178767 nnns volume:73 year:2023 number:5 pages:390-403 https://doi.org/10.5937/arhfarm73-46686 kostenfrei https://doaj.org/article/9f518f6a5835435db58f8c14d2af54f0 kostenfrei https://scindeks-clanci.ceon.rs/data/pdf/0004-1963/2023/0004-19632305390N.pdf kostenfrei https://doaj.org/toc/0004-1963 Journal toc kostenfrei https://doaj.org/toc/2217-8767 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 73 2023 5 390-403 |
| allfieldsSound |
10.5937/arhfarm73-46686 doi (DE-627)DOAJ099418371 (DE-599)DOAJ9f518f6a5835435db58f8c14d2af54f0 DE-627 ger DE-627 rakwb srp RS1-441 Nikolić Ines verfasserin aut The landscape of nanomedicines: An expert perspective 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The field of nanotechnology is at the forefront of a scientific revolution, where the term "nano" transcends mere size and opens the door to enormous possibilities. In the context of drug development, the selection of a suitable drug delivery system (corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly, nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining recognition for addressing healthcare issues. While these products hold immense promise, they have faced certain complexities in their translation from the preclinical to the clinical setting, reflected in the lack of proper assessment protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their significance. However, the relatively modest number of approved nanomedicines compared to the extensive research efforts raises important questions and underscores areas of uncertainty. This article provides an overview of the challenges in defining nanomedicines, their properties, the complexities of regulatory frameworks, and the imperative for standardized characterization protocols. nanomedicines nanoparticles characterization protocols regulation of nanomedicines Pharmacy and materia medica Filipić Brankica verfasserin aut Petrović Marija verfasserin aut Jordan Olivier verfasserin aut Savić Snežana verfasserin aut Borchard Gerrit verfasserin aut In Arhiv za farmaciju Pharmaceutical Association of Serbia, Belgrade, Serbia, 2018 73(2023), 5, Seite 390-403 (DE-627)1692190660 22178767 nnns volume:73 year:2023 number:5 pages:390-403 https://doi.org/10.5937/arhfarm73-46686 kostenfrei https://doaj.org/article/9f518f6a5835435db58f8c14d2af54f0 kostenfrei https://scindeks-clanci.ceon.rs/data/pdf/0004-1963/2023/0004-19632305390N.pdf kostenfrei https://doaj.org/toc/0004-1963 Journal toc kostenfrei https://doaj.org/toc/2217-8767 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 73 2023 5 390-403 |
| source |
In Arhiv za farmaciju 73(2023), 5, Seite 390-403 volume:73 year:2023 number:5 pages:390-403 |
| sourceStr |
In Arhiv za farmaciju 73(2023), 5, Seite 390-403 volume:73 year:2023 number:5 pages:390-403 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
nanomedicines nanoparticles characterization protocols regulation of nanomedicines Pharmacy and materia medica |
| isfreeaccess_bool |
true |
| container_title |
Arhiv za farmaciju |
| authorswithroles_txt_mv |
Nikolić Ines @@aut@@ Filipić Brankica @@aut@@ Petrović Marija @@aut@@ Jordan Olivier @@aut@@ Savić Snežana @@aut@@ Borchard Gerrit @@aut@@ |
| publishDateDaySort_date |
2023-01-01T00:00:00Z |
| hierarchy_top_id |
1692190660 |
| id |
DOAJ099418371 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ099418371</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414031918.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx |||||o 00| ||srp c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.5937/arhfarm73-46686</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ099418371</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9f518f6a5835435db58f8c14d2af54f0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">srp</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Nikolić Ines</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The landscape of nanomedicines: An expert perspective</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The field of nanotechnology is at the forefront of a scientific revolution, where the term "nano" transcends mere size and opens the door to enormous possibilities. In the context of drug development, the selection of a suitable drug delivery system (corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly, nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining recognition for addressing healthcare issues. While these products hold immense promise, they have faced certain complexities in their translation from the preclinical to the clinical setting, reflected in the lack of proper assessment protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their significance. However, the relatively modest number of approved nanomedicines compared to the extensive research efforts raises important questions and underscores areas of uncertainty. This article provides an overview of the challenges in defining nanomedicines, their properties, the complexities of regulatory frameworks, and the imperative for standardized characterization protocols.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nanomedicines</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nanoparticles</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">characterization protocols</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">regulation of nanomedicines</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Filipić Brankica</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Petrović Marija</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jordan Olivier</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Savić Snežana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Borchard Gerrit</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Arhiv za farmaciju</subfield><subfield code="d">Pharmaceutical Association of Serbia, Belgrade, Serbia, 2018</subfield><subfield code="g">73(2023), 5, Seite 390-403</subfield><subfield code="w">(DE-627)1692190660</subfield><subfield code="x">22178767</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:73</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:390-403</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.5937/arhfarm73-46686</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9f518f6a5835435db58f8c14d2af54f0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://scindeks-clanci.ceon.rs/data/pdf/0004-1963/2023/0004-19632305390N.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0004-1963</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2217-8767</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">73</subfield><subfield code="j">2023</subfield><subfield code="e">5</subfield><subfield code="h">390-403</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Nikolić Ines |
| spellingShingle |
Nikolić Ines misc RS1-441 misc nanomedicines misc nanoparticles misc characterization protocols misc regulation of nanomedicines misc Pharmacy and materia medica The landscape of nanomedicines: An expert perspective |
| authorStr |
Nikolić Ines |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1692190660 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RS1-441 |
| illustrated |
Not Illustrated |
| issn |
22178767 |
| topic_title |
RS1-441 The landscape of nanomedicines: An expert perspective nanomedicines nanoparticles characterization protocols regulation of nanomedicines |
| topic |
misc RS1-441 misc nanomedicines misc nanoparticles misc characterization protocols misc regulation of nanomedicines misc Pharmacy and materia medica |
| topic_unstemmed |
misc RS1-441 misc nanomedicines misc nanoparticles misc characterization protocols misc regulation of nanomedicines misc Pharmacy and materia medica |
| topic_browse |
misc RS1-441 misc nanomedicines misc nanoparticles misc characterization protocols misc regulation of nanomedicines misc Pharmacy and materia medica |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Arhiv za farmaciju |
| hierarchy_parent_id |
1692190660 |
| hierarchy_top_title |
Arhiv za farmaciju |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1692190660 |
| title |
The landscape of nanomedicines: An expert perspective |
| ctrlnum |
(DE-627)DOAJ099418371 (DE-599)DOAJ9f518f6a5835435db58f8c14d2af54f0 |
| title_full |
The landscape of nanomedicines: An expert perspective |
| author_sort |
Nikolić Ines |
| journal |
Arhiv za farmaciju |
| journalStr |
Arhiv za farmaciju |
| callnumber-first-code |
R |
| lang_code |
srp |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2023 |
| contenttype_str_mv |
txt |
| container_start_page |
390 |
| author_browse |
Nikolić Ines Filipić Brankica Petrović Marija Jordan Olivier Savić Snežana Borchard Gerrit |
| container_volume |
73 |
| class |
RS1-441 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Nikolić Ines |
| doi_str_mv |
10.5937/arhfarm73-46686 |
| author2-role |
verfasserin |
| title_sort |
landscape of nanomedicines: an expert perspective |
| callnumber |
RS1-441 |
| title_auth |
The landscape of nanomedicines: An expert perspective |
| abstract |
The field of nanotechnology is at the forefront of a scientific revolution, where the term "nano" transcends mere size and opens the door to enormous possibilities. In the context of drug development, the selection of a suitable drug delivery system (corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly, nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining recognition for addressing healthcare issues. While these products hold immense promise, they have faced certain complexities in their translation from the preclinical to the clinical setting, reflected in the lack of proper assessment protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their significance. However, the relatively modest number of approved nanomedicines compared to the extensive research efforts raises important questions and underscores areas of uncertainty. This article provides an overview of the challenges in defining nanomedicines, their properties, the complexities of regulatory frameworks, and the imperative for standardized characterization protocols. |
| abstractGer |
The field of nanotechnology is at the forefront of a scientific revolution, where the term "nano" transcends mere size and opens the door to enormous possibilities. In the context of drug development, the selection of a suitable drug delivery system (corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly, nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining recognition for addressing healthcare issues. While these products hold immense promise, they have faced certain complexities in their translation from the preclinical to the clinical setting, reflected in the lack of proper assessment protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their significance. However, the relatively modest number of approved nanomedicines compared to the extensive research efforts raises important questions and underscores areas of uncertainty. This article provides an overview of the challenges in defining nanomedicines, their properties, the complexities of regulatory frameworks, and the imperative for standardized characterization protocols. |
| abstract_unstemmed |
The field of nanotechnology is at the forefront of a scientific revolution, where the term "nano" transcends mere size and opens the door to enormous possibilities. In the context of drug development, the selection of a suitable drug delivery system (corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly, nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining recognition for addressing healthcare issues. While these products hold immense promise, they have faced certain complexities in their translation from the preclinical to the clinical setting, reflected in the lack of proper assessment protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their significance. However, the relatively modest number of approved nanomedicines compared to the extensive research efforts raises important questions and underscores areas of uncertainty. This article provides an overview of the challenges in defining nanomedicines, their properties, the complexities of regulatory frameworks, and the imperative for standardized characterization protocols. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
5 |
| title_short |
The landscape of nanomedicines: An expert perspective |
| url |
https://doi.org/10.5937/arhfarm73-46686 https://doaj.org/article/9f518f6a5835435db58f8c14d2af54f0 https://scindeks-clanci.ceon.rs/data/pdf/0004-1963/2023/0004-19632305390N.pdf https://doaj.org/toc/0004-1963 https://doaj.org/toc/2217-8767 |
| remote_bool |
true |
| author2 |
Filipić Brankica Petrović Marija Jordan Olivier Savić Snežana Borchard Gerrit |
| author2Str |
Filipić Brankica Petrović Marija Jordan Olivier Savić Snežana Borchard Gerrit |
| ppnlink |
1692190660 |
| callnumber-subject |
RS - Pharmacy |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.5937/arhfarm73-46686 |
| callnumber-a |
RS1-441 |
| up_date |
2024-07-03T22:41:22.198Z |
| _version_ |
1803599460118298624 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ099418371</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414031918.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx |||||o 00| ||srp c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.5937/arhfarm73-46686</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ099418371</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9f518f6a5835435db58f8c14d2af54f0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">srp</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Nikolić Ines</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The landscape of nanomedicines: An expert perspective</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The field of nanotechnology is at the forefront of a scientific revolution, where the term "nano" transcends mere size and opens the door to enormous possibilities. In the context of drug development, the selection of a suitable drug delivery system (corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly, nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining recognition for addressing healthcare issues. While these products hold immense promise, they have faced certain complexities in their translation from the preclinical to the clinical setting, reflected in the lack of proper assessment protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their significance. However, the relatively modest number of approved nanomedicines compared to the extensive research efforts raises important questions and underscores areas of uncertainty. This article provides an overview of the challenges in defining nanomedicines, their properties, the complexities of regulatory frameworks, and the imperative for standardized characterization protocols.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nanomedicines</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nanoparticles</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">characterization protocols</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">regulation of nanomedicines</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Filipić Brankica</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Petrović Marija</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jordan Olivier</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Savić Snežana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Borchard Gerrit</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Arhiv za farmaciju</subfield><subfield code="d">Pharmaceutical Association of Serbia, Belgrade, Serbia, 2018</subfield><subfield code="g">73(2023), 5, Seite 390-403</subfield><subfield code="w">(DE-627)1692190660</subfield><subfield code="x">22178767</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:73</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:390-403</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.5937/arhfarm73-46686</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9f518f6a5835435db58f8c14d2af54f0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://scindeks-clanci.ceon.rs/data/pdf/0004-1963/2023/0004-19632305390N.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0004-1963</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2217-8767</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">73</subfield><subfield code="j">2023</subfield><subfield code="e">5</subfield><subfield code="h">390-403</subfield></datafield></record></collection>
|
| score |
7.3995275 |